Mateon Therapeutics (OTCMKTS: MATN) and Grifols SA, Barcelona (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.
Insider and Institutional Ownership
22.5% of Grifols SA, Barcelona shares are held by institutional investors. 4.5% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Mateon Therapeutics does not pay a dividend. Grifols SA, Barcelona pays out 30.1% of its earnings in the form of a dividend.
This is a summary of current ratings for Mateon Therapeutics and Grifols SA, Barcelona, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Grifols SA, Barcelona||0||1||3||0||2.75|
Mateon Therapeutics presently has a consensus price target of $1.75, indicating a potential upside of 872.22%. Given Mateon Therapeutics’ higher possible upside, equities research analysts clearly believe Mateon Therapeutics is more favorable than Grifols SA, Barcelona.
Valuation & Earnings
This table compares Mateon Therapeutics and Grifols SA, Barcelona’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||N/A||-$13.65 million||($0.56)||-0.32|
|Grifols SA, Barcelona||$4.48 billion||3.31||$603.60 million||$0.93||23.37|
Grifols SA, Barcelona has higher revenue and earnings than Mateon Therapeutics. Mateon Therapeutics is trading at a lower price-to-earnings ratio than Grifols SA, Barcelona, indicating that it is currently the more affordable of the two stocks.
This table compares Mateon Therapeutics and Grifols SA, Barcelona’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Grifols SA, Barcelona||13.16%||18.08%||6.22%|
Risk & Volatility
Mateon Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Grifols SA, Barcelona has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Grifols SA, Barcelona beats Mateon Therapeutics on 8 of the 12 factors compared between the two stocks.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Grifols SA, Barcelona Company Profile
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.